PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan 'Enabling Technology of the Year Award 2006' Goes to Swiss Pharma Startup AmVac AG - In the future, the arrival of new vaccines will result in operating margins that are at least on par with the pharma sector. The vaccines market is expected to demonstrate a CAGR of 13 per cent between 2006 and 2010
Frost & Sullivan 'Enabling Technology of the Year Award 2006' Goes to Swiss Pharma Startup AmVac AG

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/02/22 - In the future, the arrival of new vaccines will result in operating margins that are at least on par with the pharma sector. The vaccines market is expected to demonstrate a CAGR of 13 per cent between 2006 and 2010.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

AmVac has developed two biotherapeutic drugs already close to market approval which have the potential to become the new gold-standard technology in their indications. The award is given to AmVac for its outstanding works focused on the development of these biotherapeutic vaccines and treatment procedures. In presenting this award, Frost & Sullivan commends the company's proactive efforts in leveraging its knowledge in revolutionary drug discovery to resolve major bottlenecks in drug research and clinical application.

In the future, the arrival of new vaccines will result in operating margins that are at least on par with the pharma sector. The vaccines market is expected to demonstrate a CAGR of 13 per cent between 2006 and 2010. Rapid growth is anticipated in the vaccine therapeutics segment and accordingly, AmVac is poised for strong growth especially in combination with their unique indications focused on.

"AmVac has developed a portfolio of advanced products, which focus on safe and efficient applications in Urology and Gynecology," notes Frost & Sullivan Drug Discovery Technologies Programme Leader, Dr. Amarpreet Dhiman. "It focuses on those applications, where safety is particularly important, such as identifying infectious diseases that cover unmet therapeutic needs in the life sciences market."

Melinda Karpati, CEO of AmVac claims: "Over the last year, we and our partners were able to advance two innovative treatment regimens with our products while maintaining a lean but effective research and development process. Therefore we are very proud that our efforts are recognized and honoured by experts with this unique award."

The company's two principal instrument platforms Femivac® and Prostavac® have been developed and tested through collaborations with biotechnology companies and academic institutions. Femivac®, the immune-therapeutic vaccine for the treatment of Bacterial Vaginosis and Trichomoniasis has shown convincing efficacy and safety profiles with sustained protectiveness and higher effectiveness compared to commonly used drugs.

Prostavac® is the world's first patented immune-therapeutic vaccine for the treatment of Benign Prostatic Hyperplasia (BPH) and acute/chronic Prostatitis. It has shown a high success rate with 75 per cent of patients showing sustainable improvements, with marginal side effects and no surgery. Due to these factors, it has the potential to become an industry standard.

"In integrating both novel effective therapeutics and sustainable and safe medicine, thereby ushering in unmatched productivity with robustness, AmVac has been brought to the forefront of the industry," remarks Dr. Dhiman. "The company has varied application capabilities that can bring safer drugs to the market with a faster turn-around time and target different disease indications in the future."

Collaborating with several external partners, AmVac's proprietary technology has received heightened appreciation in many applications, including life research reachable and academia, fulfilling current biomarker expedition and bestowing more strategically designed screening abilities.

The Frost & Sullivan Enabling Technology of the Year Award is presented to a company that has developed a technology that can benefit or revolutionise the industry. The Award recipient has developed, through its research partners, a system that enables the development of new therapies for the treatment of crucial diseases in the human reproductive system. This breakthrough allows clinical researchers to develop procedures that allow advantages for health staff and patients on an unprecedented scale.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

About AmVac
AmVac is a biopharmaceutical company located in Zug/Swiss. The goal of the company is the development and distribution of innovative drugs in the therapeutic indications urology and gynaecology. In these indications exists a high unmet medical need. AmVac's specific expertise is the identification of innovative drugs and therapies. These will be in licensed and brought to market through focussed clinical development studies and approval expertise. AmVac has built already a balanced portfolio with advanced products. The early pipeline is further completed through an effective network with dedicated collaboration partners in leading research groups and biotech companies.

Contact AmVac

Ms. Beatrice Roth, AMVAC AG
Tel. +41-41-725-32-30
roth[.]amvac.ch

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan 'Enabling Technology of the Year Award 2006' Goes to Swiss Pharma Startup AmVac AG

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

AmVac | Frost & Sullivan
Publisher Contact: Anna Lay 
+49(0)69-770-33-12 anna.lay[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)